#CPIX

CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH Cumberland Pharmaceuticals (Nasdaq: CPIX) reported Q4 2025 combined net revenues of $13.7M, up 31% year-over-year, and full-year 2025 net revenues of $44.5M, up 18% versus 2024. The company posted a $2.9M net loss for 2025 and $1.7M adjusted earnings. Total assets were $76.8M and shareholders' equity was $24.9M at year end.Key developments: international launches/approvals, Talicia co-commercialization, permanent J-code for Caldolor, positive FIGHT DMD Phase II topline results and FDA fast track designation in early 2026.

1 week ago

#CPIX CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH

www.stocktitan.net/news/CPIX/cumberland-pha...

0 0 0 0

CALDOLOR® (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT Cumberland Pharmaceuticals (Nasdaq: CPIX) announced on Dec 8, 2025 that Caldolor® (ibuprofen) Injection's permanent J-code J1741 is now officially associated with a reimbursement price, creating a CMS-covered, non-opioid option for pain and fever management.The update links an established reimbursement price to J1741, which the company says supports opioid-sparing strategies, encourages providers to update billing systems, and may improve access to Caldolor for adult and pediatric patients where ibuprofen is indicated.

3 months ago

#CPIX CALDOLOR® (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT

www.stocktitan.net/news/CPIX/caldolor-ibupr...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

4 months ago

Trade Alert, Wednesday November 5, 2025 – Crystal Equity Research

Small-cap stocks in new downtrend, Av Dir Indx, Wed Nov 5th - #SNDL #PNRG #NNOX #MCRB #LCUT #KRNT #HEPS #CPIX #DEFT #ELTX #GSM #VYGR #BAND #ABEO #BBAI #SI #PRG #ONTF #MVO #MNTN #HPP #FPI #CABO #TIL - More: crystalequityresearch.com/trade-alert-... - #smallcap

0 0 0 0

CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH NASHVILLE, Tenn., Nov. 4, 2025/ PRNewswire/-- Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $8.3 million during the third quarter of 2025. Year-to-date revenues for the first nine months of the year totaled $30.8 million, representing an...

4 months ago

#CPIX CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH

www.stocktitan.net/news/CPIX/cumberland-pha...

0 0 0 0

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE NASHVILLE, Tenn., Oct. 28, 2025/ PRNewswire/-- Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, announced today that it will release its third quarter 2025 financial results and provide a Company update after the market closes on Tuesday, Nov. 4, 2025.. A conference call will be held on Nov. 4 at 4:30 p.m. Eastern Time to discuss the results and...

4 months ago

#CPIX CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE

www.stocktitan.net/news/CPIX/cumberland-pha...

0 0 0 0

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO NASHVILLE, Tenn., Oct. 20, 2025/ PRNewswire/-- Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced strategic arrangements with RedHill Biopharma Ltd., a specialty biopharmaceutical company, to jointly commercialize Talicia ®. The FDA-approved oral capsule is...

4 months ago

#CPIX #RDHL CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

www.stocktitan.net/news/CPIX/cumberland-pha...

0 0 0 0

RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal RedHill (NASDAQ: RDHL) announced a strategic partnership with Cumberland Pharmaceuticals (NASDAQ: CPIX) on Oct 20, 2025 in which Cumberland will invest $4.0 million for a 30% ownership stake and joint control of RedHill's Talicia business, with RedHill retaining 70%.The companies agreed an equal-sharing U.S. co-commercialization deal for Talicia's net revenues, with Cumberland providing national sales, marketing and operational support. Talicia is patent protected through 2042 and holds eight years of U.S. QIDP exclusivity. The transaction also contributes to RedHill's belief that it has stockholders' equity above the $2.5 million Nasdaq continued-listing threshold as of the press release date.

4 months ago

#RDHL #RDHL #CPIX RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal

www.stocktitan.net/news/RDHL/red-hill-s-tal...

0 0 0 0

CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC. Cumberland Pharmaceuticals (NASDAQ:CPIX) announced that its antibiotic Vibativ (telavancin) was added to a national group purchasing agreement with Premier, Inc., effective October 1, 2025.Premier membership includes about 4,350 U.S. hospitals and 325,000 other providers; the agreement makes Premier’s pre‑negotiated pricing and terms available to members for Vibativ in both the existing 12‑vial carton and a newly introduced 4‑vial Starter Pak, intended to support inpatient and outpatient ordering flexibility and inventory management.

5 months ago

#CPIX CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.

www.stocktitan.net/news/CPIX/cumberland-pha...

0 0 0 0

Non-Opioid Pain Management Breakthrough: Cumberland's Injectable Ibuprofen Approved in Mexican Market Cumberland partners with PiSA Farmaceutica to distribute 800mg injectable ibuprofen in Mexico, offering non-opioid pain management for hospital settings. Product reduces post-operative pain and opioid needs.

5 months ago

#CPIX CUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO

www.stocktitan.net/news/CPIX/cumberland-pha...

0 0 0 0

Revolutionary Drug-Resistant Bacteria Fighter: Tabuk Brings Vibativ Antibiotic to Saudi Healthcare System Tabuk introduces Vibativ injection for pneumonia and skin infections, effective against MRSA and drug-resistant bacteria. Once-daily dosing, no monitoring needed. Maintains potency after 10 years.

5 months ago

#CPIX TABUK LAUNCHES VIBATIV® FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIA

www.stocktitan.net/news/CPIX/tabuk-launches...

0 0 0 0

Cumberland Pharmaceuticals Hits 23% Revenue Growth as DMD Drug Shows Major Heart Benefits Q2 earnings reveal 23% YTD growth while new DMD treatment shows promising cardiac results. Multiple pipeline developments advance across portfolio. Get full details.

7 months ago

#CPIX Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date

www.stocktitan.net/news/CPIX/cumberland-pha...

0 0 0 0

CUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK Cumberland Pharmaceuticals (NASDAQ: CPIX) has secured a significant contract with Vizient, the nation's largest healthcare performance improvement company, for its new Vibativ® 4-Vial Starter Pak. Vizient serves over 65% of U.S. acute care providers, including 97% of academic medical centers.Vibativ® is an FDA-approved injectable antibiotic for treating hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) and complicated skin infections caused by Gram-positive pathogens, including MRSA. The drug has demonstrated significantly higher cure rates compared to vancomycin in HABP/VABP cases with specific pathogen profiles.This contract enhances accessibility to Vibativ's new 4-vial configuration, supporting flexible treatment initiation across inpatient and outpatient settings.

7 months ago

#CPIX CUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK

www.stocktitan.net/news/CPIX/cumberland-pha...

0 0 0 0

Cumberland Pharmaceuticals Sets Q2 Earnings Date: FDA-Approved Drug Portfolio Update Coming August 5 Specialty pharma company Cumberland to discuss Q2 2025 results and pipeline updates on August 5. Conference call registration now open. Get insights.

7 months ago

#CPIX CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE

www.stocktitan.net/news/CPIX/cumberland-pha...

0 0 0 0

PRISM MarketView

@prismmarketview.bsky.social

8 months ago

PRISM Mid-Day Movers:
#DaréBioscience ( #DARE) soared 89%
#SolunaHoldings ( #SLNH) dropped 20%
Other PRISM Mid-Day Movers:
#CumberlandPharmaceuticals Inc. ( #CPIX) up 20.24%
#BitdeerTechnologiesGroup ( #BTCM) up 17.17%
#ProKidneyCorp. ( #PROK) down 15.42%

prismmarketview.com/prism-mid-da...

0 0 0 0

Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference Cumberland Pharmaceuticals (NASDAQ: CPIX) presented positive Phase 2 FIGHT DMD trial results for ifetroban, their novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease, at the PPMD conference. The trial showed a significant 5.4% improvement in left ventricular ejection fraction with high-dose ifetroban compared to control groups. The drug demonstrated reduced cardiac damage markers while being well-tolerated, with all patients opting to continue treatment in the open-label extension. Ifetroban, which has received both Orphan Drug and Rare Pediatric Disease Designations from the FDA, works by blocking the thromboxane receptor involved in inflammation and fibrosis. The results are particularly significant as DMD-related heart disease, currently without approved treatments, is the leading cause of death in DMD patients.

8 months ago

#CPIX Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference

www.stocktitan.net/news/CPIX/cumberland-pha...

0 0 0 0

Pain Management Breakthrough: New Study Shows 23% Less Morphine Needed in Elderly Patients Using Caldolor Clinical data reveals significant opioid reduction and enhanced safety profile in patients over 60. See how this IV pain medication is transforming elderly care. Get insights.

9 months ago

#CPIX NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS

www.stocktitan.net/news/CPIX/new-study-find...

0 0 0 0

Cumberland Pharmaceuticals Leverages AI Technology to Transform IPF Treatment Research in Major Clinical Trial New AI-powered imaging analytics enhance Phase II trial for innovative IPF treatment targeting 2M patients worldwide. See how deep learning transforms clinical data.

10 months ago

#CPIX CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH

www.stocktitan.net/news/CPIX/cumberland-pha...

0 0 0 0

Cumberland Pharmaceuticals Hits Triple Win: 38% Revenue Jump, DMD Breakthrough, and China Market Entry Latest earnings reveal strong growth plus breakthrough DMD trial results. Cumberland expands to China market with Vibativ approval. See full financial metrics and pipeline updates.

10 months ago

#CPIX Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025

www.stocktitan.net/news/CPIX/cumberland-pha...

0 0 0 0

Breakthrough DMD Heart Disease Treatment Achieves 5.4% Function Boost While Controls Decline Cumberland's ifetroban demonstrates significant cardiac benefits in DMD patients, securing rare pediatric and orphan drug designations. First potential therapy for DMD heart disease.

11 months ago

#CPIX FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference

www.stocktitan.net/news/CPIX/fight-dmd-tria...

0 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

News; ( NASDAQ: #CPIX ) Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth

0 0 0 0

Cumberland's Revenue Climbs 11.6% as Pipeline Advances: Are Positive Clinical Results the Turning Point? Cumberland achieves $10.4M Q4 revenue with promising ifetroban study results and Vibativ China approval, while working to overcome $6.4M annual loss.

1 year ago

#CPIX Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth

www.stocktitan.net/news/CPIX/cumberland-pha...

0 0 0 0

Game-Changing Antibiotic Enters China: Cumberland's Weapon Against Deadly Drug-Resistant Infections Gets Green Light FDA-approved Vibativ gains access to world's second-largest market, showing superior efficacy against resistant bacteria with higher cure rates than competitors

1 year ago

#CPIX VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA

www.stocktitan.net/news/CPIX/vibativ-receiv...

0 0 0 0

1 year ago

🚀 Exciting times for #CPIX! With promising phase 2 trial results for ifetroban, bullish momentum is building. Trading above key moving averages and a strong RSI of 65, it's showing buying pressure. Consider entering at $4.25, targeting $4.50 & $4.70. Stay sharp! 📈 #Stocks #Biotech

0 0 0 0

1 year ago

🚀 Exciting times for #CPIX! With a strong bullish momentum, price soaring above key SMAs, and positive MACD, Cumberland Pharmaceuticals is on the rise! 📈 Enter at $4.50, target $5.00 & $5.30. Stop loss at $4.20. High confidence in gains! #FeetrAI #StockMarket

0 0 0 0

1 year ago

🚀 Exciting times for #CPIX! Riding high on bullish momentum from positive phase 2 results for ifetroban. With RSI near 68 and MACD showing strength, CPIX is in a strong uptrend. Consider going long at $4.50, targeting $5.00 & $5.30. Stay sharp, traders! 📈 #FeetrAI

0 0 0 0

InsiderFinance

@insiderfinance.com

1 year ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

Weekly Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #MSTR 102% OTM
2. #WULF 60% OTM
3. #CPIX 49% OTM
4. #MNMD 48% OTM
5. #CGC 42% OTM

#OptionFlow #OptionsTrading #Trading

0 0 0 0